Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 12/20 | 0.52 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.52 |
| ▸ | PDE5A | O76074 | 4/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769656 | 0.87 | PDE9A (0.50) | PDE9APDE1CPDE5ADAPK3PIM1 | |
| SCHEMBL2773649 | 0.87 | PDE9A (0.59) | PDE9APDE1CPDE5ADAPK3PIM1 | |
| SCHEMBL2771678 | 0.86 | PDE9A (0.60) | PDE9APDE1CPDE5ADAPK3PIM1 | |
| SCHEMBL13504654 | 0.86 | PDE9A (0.48) | PDE9APDE1CPDE5ADAPK3PIM1 | |
| SCHEMBL2772167 | 0.85 | PDE5A (0.48) | PDE9APDE1CPDE5ADAPK3PIM1 | |
| SCHEMBL2771903 | 0.85 | PDE9A (0.50) | PDE9APDE1CPDE5ACDK4CCND1 | |
| SCHEMBL2769898 | 0.83 | PDE9A (0.62) | PDE9APDE1CPDE5ADAPK3PIM1 | |
| SCHEMBL2770187 | 0.83 | PDE9A (0.64) | PDE9APDE1CPDE5ADAPK3PIM1 | |
| SCHEMBL2769409 | 0.83 | PDE9A (0.48) | PDE9APDE1CPDE5ACDK4CCND1 | |
| SCHEMBL2768169 | 0.82 | CDK4 (0.55) | PDE9APDE1CPDE5ADAPK3PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809348-B2 | 6-arylmethyl substituted pyrazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8809348-B2 | 6-arylmethyl substituted pyrazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8809348-B2 | 6-arylmethyl substituted pyrazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| EP-1628980-B1 | 6-ARYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-20100035900-A1 | 6-Arylmethyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035900-A1 | 6-Arylmethyl-substituted pyrazolopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-7615558-B2 | 6-arylmethylprazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615558-B2 | 6-arylmethylprazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-7615558-B2 | 6-arylmethylprazolo[3,4-d]pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20070161662-A1 | 6-Arylmethyl-substituted pyrazolopyrimidines | BAYER HEALTHCARE AG (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161662-A1 | 6-Arylmethyl-substituted pyrazolopyrimidines | BAYER HEALTHCARE AG (DE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161662-A1 | 6-Arylmethyl-substituted pyrazolopyrimidines | BAYER HEALTHCARE AG (DE) | 2007-07-12 | — | — | US | disclosed |
| EP-1628980-A1 | 6-ARYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004099210-A1 | 6-ARYLMETHYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035900-A1 | 6-Arylmethyl-substituted pyrazolopyrimidines | P2RX6, P2RY6, GRM6 | PDE9A 322/4885PDE1C 405/4885PDE5A 257/4885 |
| US-20070161662-A1 | 6-Arylmethyl-substituted pyrazolopyrimidines | P2RX6, P2RY6, GRM6 | PDE9A 322/4885PDE1C 405/4885PDE5A 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.